IN8bio's INB-100 Shows Promising Results in Leukemia Patients at EBMT 2023.

IN8bio has presented positive data from its Phase 1 trial of INB-100 in leukemia patients, showing that 100% of evaluable patients treated with INB-100 remained alive, progression-free, and in durable complete remission (CR) as of April 21, 2023. The latest data on immune reconstitution presented at the European Society for Blood and Marrow Transplantation (EBMT) showed significant allogeneic gamma-delta T cell expansion and persistence in patients through the first 180 days post-treatment. The study's updated safety data reported low-grade graft versus host disease (GvHD) in all patients treated, which was steroid-responsive, and had a more rapid onset at higher dose levels.